

protect against infection with *S. typhi*, comprising administering to said human, a composition comprising a molecular conjugate of the *S. typhi* Vi polysaccharide derived from *S. typhi* covalently bound through an adipic acid dihydrazide linker to *Pseudomonas aeruginosa* recombinant exoprotein A in a pharmaceutically acceptable carrier.

A 2 Sub B1  
3. (Amended) The method of claim 1 wherein said conjugate molecule is administered at a dose of about 3 micrograms to about 50 micrograms of *S. typhi* Vi polysaccharide.

A 3 Sub B1  
5. (Amended) The method of claim 1 wherein the antibodies protect the human against infection by *S. typhi*.

A 4 Sub B1  
12. (Amended) A method for vaccinating a human against *S. typhi* infection, comprising administering to the human an immunizing amount of a composition comprising a molecular conjugate of *S. typhi* Vi polysaccharide derived from *S. typhi* covalently bound through an adipic acid dihydrazide linker to *Pseudomonas aeruginosa* recombinant exoprotein A in a pharmaceutically acceptable carrier.

A 5 Sub B1  
14. (Amended) A vaccine composition comprising an immunologically effective amount of a molecular conjugate of *S. typhi* Vi polysaccharide derived from *S. typhi* covalently bound through an adipic acid dihydrazide linker to *Pseudomonas aeruginosa* recombinant exoprotein A, in a pharmaceutically acceptable carrier.

Sub B1  
A 6  
16. (New) The method of claim 1 or 5 wherein the human is a 2 to 3 year old.

17. (New) The method of claim 1 or 5 wherein the human is a 4 to 5 year old.